UY31306A1 - Uso de gestagenos en combinacion con (6s)-5-metiltetrahidrofolato para la terapia de la endometriosis con simultanea reduccion de los efectos colaterales terapéuticos, asi como reduccion del riesgo de malformaciones congénitas al comenzar un embarazo - Google Patents

Uso de gestagenos en combinacion con (6s)-5-metiltetrahidrofolato para la terapia de la endometriosis con simultanea reduccion de los efectos colaterales terapéuticos, asi como reduccion del riesgo de malformaciones congénitas al comenzar un embarazo

Info

Publication number
UY31306A1
UY31306A1 UY31306A UY31306A UY31306A1 UY 31306 A1 UY31306 A1 UY 31306A1 UY 31306 A UY31306 A UY 31306A UY 31306 A UY31306 A UY 31306A UY 31306 A1 UY31306 A1 UY 31306A1
Authority
UY
Uruguay
Prior art keywords
reduction
risk
gestagens
beginning
combination
Prior art date
Application number
UY31306A
Other languages
English (en)
Inventor
Zimmermann Holger
King Kristina
Diefenbach Konstanze
Wasserfall Annemarie
Seitz Christian
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38846909&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31306(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of UY31306A1 publication Critical patent/UY31306A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se usan gestágenos antiandrogénicos en una unidad de dosis diaria que equivale a como máximo el doble de la dosis inhibidora de la ovulacion en combinacion con (6)-5-metiltetrahidrofolato para obtener preparados farmacéuticos para la terapia de endometriosis con simultánea reduccion de los efectos colaterales terapéuticos, tales como la influencia negativa sobre la densidad osea/el metabolismo oseo y el riesgo de osteoporosis. En el caso de iniciado un embarazo, la reduccion del riesgo de malformaciones congénitas, como defectos del tubo neural, fisuras palatina, de labios y mandíbula, y complicaciones en el embarazo, tales como desprencimiento de placenta y aborto.
UY31306A 2007-08-24 2008-08-22 Uso de gestagenos en combinacion con (6s)-5-metiltetrahidrofolato para la terapia de la endometriosis con simultanea reduccion de los efectos colaterales terapéuticos, asi como reduccion del riesgo de malformaciones congénitas al comenzar un embarazo UY31306A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07016642A EP2027855A1 (de) 2007-08-24 2007-08-24 Verwendung von Gestagenen in Kombination mit (6S)5-Methyltetrahydrofolat zur Therapie der Endometriose mit gleichzeitiger Verminderung von Therapie-Nebenwirkungen sowie der Verminderung des Risikos angeborener Fehlbildungen bei Eintritt einer Gravidität

Publications (1)

Publication Number Publication Date
UY31306A1 true UY31306A1 (es) 2008-11-28

Family

ID=38846909

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31306A UY31306A1 (es) 2007-08-24 2008-08-22 Uso de gestagenos en combinacion con (6s)-5-metiltetrahidrofolato para la terapia de la endometriosis con simultanea reduccion de los efectos colaterales terapéuticos, asi como reduccion del riesgo de malformaciones congénitas al comenzar un embarazo

Country Status (17)

Country Link
EP (2) EP2027855A1 (es)
JP (1) JP2010536808A (es)
KR (1) KR20100047872A (es)
CN (1) CN101784271A (es)
AR (1) AR070023A1 (es)
AU (1) AU2008291406A1 (es)
BR (1) BRPI0815756A2 (es)
CA (1) CA2696030A1 (es)
CL (1) CL2008002485A1 (es)
EA (1) EA201000338A1 (es)
MX (1) MX2010002190A (es)
PA (1) PA8793901A1 (es)
PE (1) PE20090608A1 (es)
TW (1) TW200930377A (es)
UY (1) UY31306A1 (es)
WO (1) WO2009027003A1 (es)
ZA (1) ZA201002035B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101874806A (zh) * 2009-04-29 2010-11-03 北京本草天源药物研究院 一种地诺孕素固体制剂
CN108379226B (zh) * 2018-05-28 2019-11-29 上海市计划生育科学研究所 氯地孕酮自微乳组合物、其制备方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH693255A5 (de) 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
JP4418105B2 (ja) 1997-12-26 2010-02-17 持田製薬株式会社 ジエノゲストを有効成分とする血管新生抑制剤
CH693905A5 (de) 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
US20050032741A1 (en) * 2003-08-06 2005-02-10 Balaji Venkataraman Vitamin Compositions
DE102005034498A1 (de) * 2005-07-20 2007-01-25 Grünenthal GmbH Orale Kontrazeption mit Trimegeston
DE102005053771A1 (de) * 2005-11-09 2007-05-10 Grünenthal GmbH Darreichform zur hormonalen Kontrazeption

Also Published As

Publication number Publication date
ZA201002035B (en) 2012-09-26
PA8793901A1 (es) 2009-04-23
WO2009027003A1 (de) 2009-03-05
JP2010536808A (ja) 2010-12-02
KR20100047872A (ko) 2010-05-10
EP2027855A1 (de) 2009-02-25
AR070023A1 (es) 2010-03-10
BRPI0815756A2 (pt) 2015-02-18
TW200930377A (en) 2009-07-16
CA2696030A1 (en) 2009-03-05
AU2008291406A1 (en) 2009-03-05
MX2010002190A (es) 2010-03-17
EA201000338A1 (ru) 2010-08-30
EP2194978A1 (de) 2010-06-16
PE20090608A1 (es) 2009-06-12
CL2008002485A1 (es) 2009-11-20
CN101784271A (zh) 2010-07-21

Similar Documents

Publication Publication Date Title
ES2540751T3 (es) Composición para mejorar la función sexual masculina que contiene extracto de baya de ginseng
PE20211588A1 (es) Compuestos y sus usos para aliviar sintomas asociados a la menopausia
CR7611A (es) Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona
CL2011003291A1 (es) Composicion farmaceutica de dosis unica que contiene a) como gestageno 50-90 µg de levonorgestrel y b) como inhibidor cox (ciclooxigenasa) 5-60 mg de piroxicam, 50-600 mg de indometacina o 40-450 mg de diclofenaco; y su uso para preparar medicamentos para la anticoncepcion en caso de emergencia.
CL2016001411A1 (es) Unidad de dosificación farmacéutica solida de desintegración oral que comprende un componente de estetrol; metodo de preparación; uso para la anticoncepción femenina y en terápia de sustitución hormonal femenina.
ATE540680T1 (de) Pharmazeutische aripiprazol-zusammensetzungen
SG152288A1 (en) Management of breakthrough bleeding in extended hormonal contraceptive regimens
DOP2006000110A (es) Composición farmaceútica que contiene gestágenos y/o estrógenos y 5-metil-(6s)-tetrahidrofolato
PE20040068A1 (es) Decanoato, undecanoato y dodecanoato de etonogestrel
AR023806A1 (es) Uso de una mezcla de peptidos para la manufactura de un agente terapeutico para la profilaxis y/o el tratamiento del cancer, las composicionesfarmaceuticas y vacunas que contienen dicha mezcla y los procedimientos de preparacion de dichas composiciones y vacunas
AR061959A1 (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
AR022589A1 (es) UNA CÁPSULA QUE COMPRENDE UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL, UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL Y EL USO PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
CO6220945A2 (es) Uso de una composicion que comprende formoterol y dipropianato de beclometasona para la prevencion y/o tratamiento de una exacerbacion de asma
UY31306A1 (es) Uso de gestagenos en combinacion con (6s)-5-metiltetrahidrofolato para la terapia de la endometriosis con simultanea reduccion de los efectos colaterales terapéuticos, asi como reduccion del riesgo de malformaciones congénitas al comenzar un embarazo
CL2007002878A1 (es) Agente farmaceutico que comprende 1) un inhibidor de her2 que tiene un esqueleto de pirrolopirimidina o de pirazolopirimidina y 2) un agente terapeutico hormonal o anticancerigeno en combinacion; y uso pra la prevencion o el tratamiento del cancer.
AR066778A1 (es) Terapia combinada para el tratamiento del cancer que comprende vinflunina y trastuzumab
CO7111317A2 (es) Método para el tratamiento de enfermedades ginecológicas
PT1220676E (pt) Prevencao do cancro colorrectal
PE20050191A1 (es) Composicion farmaceutica que comprende dipiridamol, acido acetilsalicilico y un antagonista de angiotensina ii
ECSP099482A (es) Preparación farmacéutica para reducir la endometriosis
PL1933843T3 (pl) Wykorzystanie walerianianu estradiolu lub estradiolu w kombinacji z dienogestem do doustnej terapii czynnościowego krwawienia macicznego w formie doustnej antykoncepcji
AR059577A1 (es) Agente de aceleracion de absorcion del calcio
TW200744609A (en) Process for producing a single-phase pharmaceutical product for oral therapy of dysfunctional uterine bleeding
AR063712A1 (es) Tratamiento del dolor usando satraplatino

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20171011